Childhood Hematopoietic Cell Transplantation (PDQ®)–Health Professional Version

Changes to This Summary (11/15/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was reformatted.

Allogeneic Hematopoietic Cell Transplantation (HCT)

Revised Table 1 to clarify HLA antigen and allele designations (i.e., HLA B 35:01—35 is the antigen and 01 is the allele).

Added text to state that rejections were rare in pediatric patients, and there were not sufficient numbers of patients to draw specific conclusions about rejection risk in children who received bone marrow.

Added text about the presentation and treatment of cytokine release syndrome.

Late Effects After HCT in Children

Added Faraci et al. and Enright et al. as references 115 and 116, respectively.

Added Baker et al. as reference 121.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary